Substandard medicines in resource-poor settings: A problem that can no longer be ignored by Caudron, J M et al.
Review
Substandard medicines in resource-poor settings: a problem
that can no longer be ignored
J.-M. Caudron
1,2, N. Ford
1, M. Henkens
1, C. Mace ´
1, R. Kiddle-Monroe
1 and J. Pinel
1,2
1 Me ´decins Sans Frontie `res, Geneva, Switzerland
2 AEDES Foundation, Brussels, Belgium
Summary The circulation of substandard medicines in the developing world is a serious clinical and public health
concern. Problems include under or over concentration of ingredients, contamination, poor quality
ingredients, poor stability and inadequate packaging. There are multiple causes. Drugs manufactured for
export are not regulated to the same standard as those for domestic use, while regulatory agencies in the
less-developed world are poorly equipped to assess and address the problem. A number of recent
initiatives have been established to address the problem, most notably the WHO pre-qualiﬁcation
programme. However, much more action is required. Donors should encourage their partners to include
more explicit quality requirements in their tender mechanisms, while purchasers should insist that
producers and distributors supply drugs that comply with international quality standards. Governments
in rich countries should not tolerate the export of substandard pharmaceutical products to poor countries,
while developing country governments should improve their ability to detect substandard medicines.
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Introduction
In October 2004 a doctor working for Me ´decins Sans
Frontie `res (MSF) in Darfur reported that a local donation
of Ringer’s lactate infusions was contaminated with a
fungal growth. Subsequent investigations revealed that
weaknesses in the bottling and quality control procedure
during manufacture led to the contamination. The product
then passed through three intermediates, including one UN
agency, before being offered to relief agencies in Darfur,
only one of which reported the problem. The World Health
Organization (WHO) and the supplier jointly issued a
recall of the contaminated batches. Six months after the
recall, however, less than 15% (2200 of 15 000 bottles) of
the contaminated product had been located.
This example illustrates the problem of substandard
medicines that is commonly confronted by health staff in
developing countries. Substandard medicines can have
serious clinical and public health consequences: contami-
nation can cause fatal toxicity (O’Brien et al. 1998); lack of
active ingredient can lead to ineffective treatment and
prolonged illness or death (Aldhous 2005); while under
dosing of active ingredient carries the additional risk of
promoting drug resistance (Laserson et al. 2001; Taylor
et al. 2001). However, the problem is very poorly
addressed compared to other problems related to quality
drug supply such as counterfeit (fake) medicines and
inappropriate drug donations (Box 1). This article high-
lights some of the key concerns derived from MSF’s work
to assure the quality of medicines for medical relief
programmes in less-developed countries, supported by a
literature review. Articles were retrieved from a PubMed
search for the phrase ‘substandard medicines’ (1988-
present) and further reﬁned with bibliographic search of
these articles.
One standard for the rich, another for the poor
In the industrialized world drug regulatory authorities have
developed strict standards and controls to ensure drugs are
effective and safe. However, in the less-developed world,
lack of human and ﬁnancial resources within the health
sector as a whole limits the capacity of drug regulatory
agencies, resulting in a suboptimally regulated environment
in which substandard drug production can persist without
detection.
Circulation of substandard drugs is further encouraged
by the fact that drugs manufactured for export are often
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for domestic use. An analysis done by the European Union
and the French Ministry of Cooperation (Andriollo et al.
1997) revealed many problems in the export legislation
from European countries to developing countries, includ-
ing imprecise controls regarding good manufacturing
practices for exported products, lack of quality control of
products that have not been marketed in Europe, and
discordant information between drugs to be exported and
drugs for European use (Andriollo et al. 1997).
A World Health Assembly Resolution in 1988
requested WHO to ‘initiate programmes for the preven-
tion and detection of the export, import, and smuggling
of… substandard pharmaceutical preparations’ (WHO
1988). More than a decade later the World Health
Assembly urged member states to ‘establish and enforce
regulations that ensure good uniform standards of quality
assurance for all pharmaceutical materials and products
manufactured in, imported to, exported from, or in
transit through their countries’ (WHO 1999a). This was
followed by a European Commission directive in 2003
stipulating that ‘all medicinal products for human use,
including medicinal products intended for export, are to
be manufactured in accordance with the principles and
guidelines of good manufacturing practices’ (European
Commission 2003).
However, the reality today is that the quality of drugs for
export from developed to developing countries is still
determined through a much less rigorous evaluation than
for the domestic market (European Commission Human-
itarian Aid Department 2006). Efﬁcacy and safety are often
not evaluated at all. Drugs destined for international aid
and development programmes are also often exempted
from regulatory control (Andriollo et al. 1997). The
expectation is that the recipient country will evaluate the
quality of the imported drug. While this may be an
acceptable expectation between rich countries, placing this
burden of responsibility on countries that do not have the
resources to do it is impractical, even exploitative.
The causes
Poor compliance with GMP standards can lead to sub-
standard production. This may be accidental (such as
human error) or the result of insufﬁcient resources
(expertise, appropriate manufacturing infrastructure, or
human and ﬁnancial resources). Other deliberate causes are
often ignored or underestimated. Quality audits of manu-
facturing sites done by MSF pharmacists (180 sites visited
over the last 4 years) have found that manufacturers that
regularly pass the most stringent inspections adjust their
standards to that of the recipient country. In our obser-
vations, parallel productions can exist in the same ‘GMP-
compliant’ facilities: a high standard of production for the
strictly regulated markets and for exacting clients such as
UN organizations and international aid agencies; an
intermediate standard of production for middle-income
countries; and a much lower standard for poorly regulated
countries.
Quality is not demanded by drug purchasers
Developing country governments often purchase drugs
without adequate reference to quality standards. While
these are available through WHO publications and via the
Internet (US Pharmacopeia 2008), local authorities in a
number of countries have expressed to us their difﬁculty in
accessing these documents and translating this information
into clauses for tenders and contracts. Non-governmental
organizations working in developing countries also issue
drug tenders without applying minimum quality assurance
Box 1 counterfeit and substandard drugs: distinct
deﬁnitions for different problems
Counterfeit⁄fake drugs: Multiple deﬁnitions have been
proposed for counterfeit drugs, with the common point
that they are the result of deliberate criminal activity,
‘deliberately and fraudulently mislabelled with respect
to identity and⁄or source’ (WHO 2006e).
Counterfeiting can apply to both branded and generic
products and may include products with the correct
ingredients or with the wrong ingredients, without
active ingredients, with insufﬁcient active ingredients or
with fake packaging (WHO 2003). The United States
Food and Drug Administration states that, ‘counterfeit
drugs are, by deﬁnition, outside of the regulatory
regime’ (Carpenter 2004), while WHO considers
counterfeiting as a serious criminal offence that puts
human lives at risk and should be combated and
punished accordingly (WHO 2006g).
Substandard drugs: According to the WHO,
‘Substandard drugs are genuine drug products which do
not meet quality speciﬁcations set for them.’ Similarly,
The United States Pharmacopoeia deﬁnes a substandard
product as a ‘legally branded or generic product, but
one that does not meet international standards for
quality, purity, strength or packaging’ (Smine 2002).
Simply put, they are as medicines that do not conform
to the pharmacopoeial standards set for them (Behrens
et al. 2002).
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Capacity for technical evaluation is limited
The World Health Organisation (WHO) estimates that
only one in six countries has fully functional drug
regulatory systems (WHO 2004a). Even relatively simple
chromatographic or pharmacopeial methods for quality
veriﬁcation (O’Brien et al. 1998) are not routinely avail-
able (Newton et al. 2006) or used effectively (Risha et al.
2006). Increasingly, drug registration is a pre-requisite for
purchase in resource-limited countries, but authorization
to register a medicine is often granted on the basis of a
simple review of documents. Quality is impossible to
assure in the absence of proper controls that at minimum
would include veriﬁcation of information submitted for
evaluation through site inspections, review of batch doc-
umentation, and random analysis of drugs supplied
(European Commission Humanitarian Aid Department
2006). Regional co-operation to improve technical capac-
ity has been proposed for over 20 years (Jayasena 1985)
but little progress has been made.
Limited pharmacovigilance capacity
In the developed world, pharmacovigilance – the detection
and prevention of adverse effects and other drug-related
problems – is an essential component of any health system,
ensuring that problems are quickly detected and resolved.
However, the setting up of a functioning pharmacovigi-
lance system, which allows for the rapid communication of
problems and recall of harmful drugs is a costly and
complicated process that has to compete with many other
pressing health system priorities in resource-limited set-
tings.
Where pharmacovigilance systems are weak or non-
existent, a higher degree of responsibility is placed on
medical staff to guard against adverse effects. Such
informal surveillance is further compromised by the acute
lack of health staff in most developing countries, where
medicines are often prescribed by necessity to patients by
health auxiliaries who only receive a very short and basic
training that does not emphasize the detection of drug side-
effects. Patients for their part often have to travel long
distances to receive medication and can rarely afford the
time or ﬁnancial cost of remaining under supervision.
Moreover, many toxic side effects are difﬁcult to detect
by clinical observation. For example, the rise in tempera-
ture often observed after post-surgery administration of
intravenous ﬂuids is usually interpreted to reﬂect a general
degradation of the patient’s condition, but we have noted
instances where this is in fact the result of a poor
manufacture of the intravenous ﬂuid resulting in contam-
ination with pyrogens.
Drug Regulatory Authorities have recently expressed
frustration at not being able to dedicate more resources to
post-marketing surveillance (WHO 2006a), all too aware
that weak pharmacovigilance limits the detection of
substandard drugs, preventing corrective action and sup-
porting their proliferation.
Diminishing number of quality manufacturers for key
essential medicines
Pharmaceutical production is proﬁt-driven, and essential
medicines are for the most part old molecules that are no
longer patent-protected, and therefore generate less proﬁt.
For example, penicillins are considered as essential drugs
by the WHO (2007a), form part of the United Nations
Interagency Emergency Health kit (WHO 2006b), and are
still used in signiﬁcant quantities in developing countries.
However, penicillin production has been progressively
abandoned in the developed world in favour of more recent
and sophisticated antibiotics such as cephalosporins, qui-
nolones, and macrolides. MSF and the UNICEF recently
assessed 11 production sites for injectable penicillins. Of
these, only two were found to be WHO GMP compliant.
The other nine sources are routinely found on the market
in Asia and Africa.
Limited understanding of the problem
In general, medical staff have little idea of the risk that
substandard products can pose to patients, and there is
signiﬁcant underreporting (Moride et al. 1997). Poor
reporting in turn reinforces a limited understanding of the
problem. Up to half of medicines tested in prevalence
surveys were substandard (Table 1), but these surveys are
rare,oftenlimitedtoafewdrugclassesandtestforanarrow
set of problems (usually concentration of active ingredient).
Common problems associated with substandard
production
Common problems associated with substandard medicines
include under or over concentration, contamination, poor
quality ingredients, poor stability and packaging problems.
Table 2 provides a summary of these problems together
with some recent examples.
A study in Nigeria (Taylor et al. 2001) found that almost
half of randomly sampled antibiotic and antiparasitic drugs
did not comply with set pharmacopoeial limits. Over and
under concentration were equally frequent, and drugs
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Country
Drugs (n = number of
different products tested)
%
Substandard
Origin of
production Stated issues References
Kenya 41 different drugs
(n = 277)
46% Kenya Failure to comply
with quality tests
Kibwage et al. (1992)
37 different drugs
(n = 102)
31% Imported Failure to comply
with quality tests
Roy (1994)
Antimalarials
(sulphadoxine-
pyrimethamine and
amodiaquine) (n = 116)
41% Not stated Under concentration
of active ingredient;
dissolution failure
Amin et al. (2005)
Antimalarials 42% India, China Over⁄under
concentration of
active ingredient
Atemnkeng et al. (2007)
DRC Antimalarials (artemisinin
derivatives) (n =7 )
14% Belgium Over⁄under
concentration of
active ingredient
Atemnkeng et al. (2007)
Bangladesh Paracetamol, ampicillin,
cotrimoxazole, vitamin B
tablets⁄injectables (n = 137)
27% Not stated Under concentration
of active ingredient
Roy (1994)
Myanmar Amoxicillin, chloroquine,
metronidazole,
paracetamol, tetracycline,
ampicillin,
chloramphenicol,
rifampicin, co-trimoxazole
and ranitidine (n = 212)
16% 21 countries
(Asia, Europe,
US and
Australia)
Under concentration
of active ingredient;
wrong active
ingredient
Wondemagegnehu (1999)
Vietnam Amoxicillin, chloroquine,
metronidazole,
paracetamol, tetracycline,
ampicillin,
chloramphenicol.
rifampicin. Diazepam,
salbutamol (n = 288)
8% 16 countries
(Asia, Europe,
Canada and
Australia)
Over⁄under
concentration of
active ingredient
Wondemagegnehu (1999)
Nigeria 21 antimalarials,
antibacterials,
antihelmitics and
antifungals (n = 581)
48% 12 countries,
(including
Europe,
Nigeria, Egypt,
Asia)
Over⁄under
concentration of
active ingredient
Taylor et al. (2001)
Chloroquine, amoxicillin,
cotrimoxazole,
tetracycline, ampiclox
(n = 81)
36% Not stated Over⁄under
concentration of
active ingredient
Shakoor et al. (1997)
Colombia,
Estonia, India,
Latvia, Russia,
Vietnam
Anti-TB drugs (n = 40) 10% Not stated Under concentration
of active ingredient
Laserson et al. (2001)
Laos Ampicillin tetracycline,
chloroquine, ASA (n = 366)
46% Laos, Thailand Over⁄under
concentration of
active ingredient
Stenson et al. (1998)
Ampicillin tetracycline,
chloroquine, ASA (n = 300)
22% Idem (repeat study) Over⁄under
concentration of
active ingredient;
over concentration
of non-active
ingredient;
disintegration
Syhakhang et al. (2004)
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Holland, Switzerland and the UK) had similarly imprecise
contents as those labelled as originating from less-devel-
oped countries.
Contamination is a recurrent problem, and can have
fatal consequences, particularly with intravenous products.
In MSF’s experience, microbial contamination of injections
and infusions is often the result of poor sterilization
management, obsolete equipment, inappropriate produc-
tion environment or too short sterilization cycles (to cut
costs). It can also be the result of poor quality packaging
materials.
Contamination of active pharmaceutical ingredient (API)
with residues of solvents used in the synthesis or other
toxic impurities is another frequent and important concern.
The quality of the API is one of the major determinants of
quality for all pharmaceuticals. However, it is also here
that compromise can lead to the greatest cost saving as
APIs can represent over 80% of the price of ﬁnished
products (Pinheiro et al. 2006).
An example is rifampicin, a key agent in the ﬁrst line
treatment against tuberculosis. Production of the API is
complex and can lead to forms of the molecule which are
not equally soluble and therefore of variable bioavailabil-
ity. This can have dramatic consequences in terms of public
health, since poorly effective drugs can lead to the
development of drug resistance. This problem has been
noted by WHO which has published guidelines for the
purchase of rifampicin-containing products (WHO 1999b;
Newton et al. 2006). Nevertheless, MSF has been con-
fronted with several sources of rifampicin (both single
ingredient and ﬁxed-dose combination tablets) that are
registered, marketed and used in many African and Asian
countries but have no proof of efﬁcacy.
Non-active ingredients (excipients) can pose as much as
a threat as active ingredients, perhaps more so given that
manufacturers are generally not required to provide any
information at all on excipients. One of the most
frequently cited cases of substandard drugs – the death of
88 children in Haiti after ingestion of paracetamol liquid –
was the consequence of a poor quality excipient. It is not
clear whether this was the result of counterfeiting or not
(O’Brien et al. 1998).
Product stability is another parameter that has a direct
inﬂuence on the quality and efﬁcacy of the medicine.
Pharmaceutical degradation is generally accelerated by
heath and humidity and WHO recommends stability
testing in tropical conditions (WHO 2006c), but this not
always done (Omer 1990; Arya 1995). Artesunate, an
essential antimalarial drug, is extremely sensitive to heat
and humidity. Stable formulations of Artesunate are
difﬁcult to produce (the quality of the packaging material is
critical) (Fawaz & Millet 2006) while co-formulations of
Artesunate with other antimalarials are even more
Table 1 (Continued)
Country
Drugs (n = number of
different products tested)
%
Substandard
Origin of
production Stated issues References
Thailand Chloroquine, amoxicillin,
cotrimoxazole,
tetracycline, ampiclox
(n = 15)
40% Not stated Over⁄under
concentration of
active ingredient
Shakoor et al. (1997)
Tanzania Antimalarials (n = 33) 36% Cyprus,
Tanzania, India,
Kenya
Under concentration
of active ingredient;
dissolution failure
Minzi et al. (2003)
Cambodia Antimalarials (n = 451) 27% 16 countries
cited
Under concentration
of active ingredient;
dissolution failure
Lon et al. (2006)
Cameroon,
Madagascar,
Chad
Antibiotics, analgesics,
antiparasitics (n = 429)
18% Not stated Over⁄under
concentration of
active ingredient;
no active ingredient
(20%);
contamination
ReMeD (1995)
Gabon, Ghana,
Kenya, Mali,
Mozambique,
Sudan,
Zimbabwe
Antimalarials chloroquine
and sulphadoxine-
pyrimethamine (n = 278)
23% Range:
9% Sudan
41% Mali
Local and
Imported
Under concentration Maponga and Ondari
(2003)
ReMeD, Re ´seau Me ´dicaments et Developpment.
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Issue Example Country
Origin of
product Reported
Over concentration TB drugs Chad Europe (6
countries),
Kenya, India
ReMeD*
Antimalarials Kenya, DRC Atemnkeng et al.
(2007)
Under concentration TB drugs Colombia, Estonia,
India, Latvia,
Russia and
Vietnam
Not stated Laserson et al. (2001)
Paracetamol, ampicilin, co-trimoxazole Bangladesh Not stated Stenson et al. (1998)
Irregular ﬁlling of
vials
Over or subdosed Thiopental Sodium
vials
Belgium (MSF
procurement centre
warehouse)
Cyprus Company alert
(1998)*
Contamination Microbial contamination of distilled
water
MFS procurement
in Europe
Hungary MSF (1999)*
Detergent contamination of i.v. ﬂuids MSF procurement
centres in Europe
UK AFSSAPS (French
DRA) and
company alert
(2003)*
Fungal contamination of i.v. ﬂuid bags MSF procurement
centres in Europe)
India MSF (2004)*
Black particles in SSG (Pentostam) vials Sudan UK Switzerland MHRA (UK DRA)
and company alert
(2006, 2007)*
Ethyl methane sulphonate (EMS)
contamination of Nelﬁnavir API and
formulations
EU and Africa EMEA (2007)*
Mislabelling (not
counterfeit)
Paracetamol tablets labelled as
co-trimoxazole
Democratic
Republic of Congo
India MSF (2007)*
Problems with
active ingredient
Variable solubility and bioavailability of
active ingredients of Rifampicin
Not stated MSF (2006)*
Morphology of the active ingredient
(furosemide) affecting the dissolution
France France,
Kyghizstan,
Kenya
Cavenaghi (1989),
Bauer et al. (2002)
Problems with
excipient
Glycerin contaminated with diethylene
glycol used in 15 000 bottles of
paracetamol liquid caused death of 88
children
Haiti Glycerin
imported
from China
via Europe
O’Brien et al. (1998)
Diethylene glycol used instead of propylene
glycol in a cough syrup killed more than
30 children in India
India India Singh et al. (2001)
Diethylene glycol used in a cough syrup
killed 21 persons in Panama
Panama Panama FDA (2006)*
Poor stability Changes in colour: amoxicillin and
clavulanic acid tablets
Georgia Cyprus MSF (2006)*
Change in smell: erythromycin tablets
(two sources)
Armenia Malta, India MSF (2004)*
Change in consistency: crystalization in
SSG vials
Sudan India MSF (2004)*
Loss of potency (measles vaccine) Nigeria UNICEF Onoja et al. (1992)
Loss of active ingredient: ergometrine
injections
Zimbabwe Not stated Nazerali and
Hogerzeil (2003)
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instability of Artesunate. MSF has found it difﬁcult to
obtain consistent stability data from producers, although
this is crucial information for guaranteeing the efﬁcacy of
the product and avoid the emergence of resistance. When
stability studies are performed they often do not adhere to
WHO guidelines, especially for the testing in zone IV
(tropical) conditions.
Efforts to address the problem
Substandard medicines represent a far larger risk to public
health than counterfeit medicines. However, with some
exceptions (Shakoor et al. 1997; Taylor et al. 2001;
Behrens et al. 2002; Kelesidis et al. 2007; Newton et al.
2008) substandard and counterfeit drugs are regularly
conﬂated and confused (Verduin-Muttiganzi & Verduin-
Muttiganzi 1998; Laserson et al. 2001; Po 2001; Figueras
et al. 2002; Wertheimer et al. 2003; Rassool 2004; Amin
et al. 2005; Videau 2006; Atemnkeng et al. 2007).
The problem of counterfeit medicines is serious, and
indeed has been described as ‘epidemic’ in the case of
artesunate in South-East Asia (Newton et al. 2008).
Determining whether a medicine is counterfeit is prob-
lematic (Behrens et al. 2002), yet the few published reports
that did differentiate between the two problems have found
that the majority of poor quality drugs were genuine, but
substandard drugs, and not the result of counterfeiting
(Wondemagegnehu 1999; Syhakhang et al. 2004;
Atemnkeng et al. 2007). One WHO study (Syhakhang
et al. 2004) found that almost all (18⁄19) poor quality
medicines were genuine products, yet this study has been
cited elsewhere by WHO as evidence of counterfeiting
(Maponga & Ondari 2003).
Because substandard drugs are frequently portrayed as a
consequence of counterfeiting, it is hardly surprising that
the majority of international attention and action is
directed at the latter. This is partly because counterfeit
drugs undermine the markets of pharmaceutical companies
who put signiﬁcant energy into tackling the problem. As a
result, WHO is promoting a global approach to combat the
problem of counterfeit medical products through reporting
procedures and enhanced access to information (WHO
1999c), and has launched a taskforce (International
Medical Products Anti-Counterfeiting Taskforce) against
counterfeit drugs (WHO 2006d). The Pan American
Health Organisation works collaboratively with the United
States against counterfeits (US Pharmacopeia 2008) and
the International Conference of Drug Regulatory Author-
ities, promoted by WHO, has incorporated the problem of
drug counterfeiting in the agendas of its meetings since
1992 (WHO 2004b).
In contrast, there is little commercial incentive to invest
in reducing the proliferation of substandard medicines, and
this remains a poorly quantiﬁed and ill addressed problem.
When actions are taken, resources are often focused on ad
hoc quality controls while what is in fact needed is a strong
quality assurance framework to ensure that the products
produced are of an acceptable quality in the ﬁrst place
(WHO 2003a). Quality control is part of quality assurance
and investing in quality control only makes sense if a
strong quality assurance system is in place.
Table 2 (Continued)
Issue Example Country
Origin of
product Reported
Packaging problems I.v. ﬂuid bottles contaminated Kenya India MSF (2002, 2003)*
Microcracks caused by wrong bottle
shape, poor quality plastic or rough
transportation
Sudan India MSF (2004)*
TB drugs moisture-damaged due to
water-permeable blister packs
India India Singh and Mohan
(2003)
Unsatisfactory
dissolution proﬁles
Higher dissolution rate of active
ingredient in antidiabetic drugs
(resulting in higher and quicker peak in
blood and toxicity)
France Cyprus, UK,
Kenya
Ba et al. (2005)
Poor dissolution of antimalarials Kenya Cyprus,
Tanzania,
India, Kenya
Amin et al. (2005)
Tanzania Minzi et al. (2003)
DRA, drug regulatory authority; ReMeD, Re ´seau Me ´dicaments et Developpement.
*Unpublished reports.
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countries must be based on a technical evaluation and
approval of the manufacturing site and the product itself.
One important step in this direction is the establishment of
the WHO pre-qualiﬁcation programme (mednet3.who.
int⁄prequal⁄) that has had a major impact on the quality
of medicines across the developing world, providing a
benchmark of quality for resource-limited countries in an
otherwise chaotic environment.
The pre-qualiﬁcation programme mobilizes a high level
of technical expertise for the evaluation of manufacturing
sites (GMP inspections) and assessment of product dos-
siers. The Global Fund and other major donors refer to the
list of WHO pre-qualiﬁcation products and encourage
countries to purchase them preferentially. In 2005 four
African countries refused to register a US Food and Drugs
Administration antiretroviral combination therapy because
the drug had not been pre-qualiﬁed by the WHO pre-
qualiﬁcation project (Donnelly 2005). To support the pre-
qualiﬁcation project, WHO has also invested signiﬁcant
resources to build capacity in developing countries through
GMP training for local inspectors and pharmacovigilance
workshops in the context of HIV⁄AIDS programmes.
Until recently the pre-qualiﬁcation project only covered
medicines for HIV⁄AIDS, TB, and malaria. Drugs for
reproductive health and avian inﬂuenza have recently been
added. However, insufﬁcient resources mean that even
within this narrow scope it is limited in the speed of the
review and quantity of drugs it is able to process.
Nevertheless, the WHO pre-qualiﬁcation programme has
given a clear signal to producers, distributors, regulators,
and health providers that essential quality standards can
and should be applied, and that the proliferation of
substandard products is not an inevitability.
Two other initiatives have recently been launched by
WHO. The Model Drug Registration Package (WHO
2007b) aims to improve understanding of drug regulatory
requirements and facilitate collaboration and technical
exchange between drug regulatory authorities in developed
and developing countries, while the Model Quality Assur-
ance System (MQAS) (WHO 2006e) provides guidelines
for procurement agencies on quality assurance and stim-
ulates exchange and collaboration between drug regulatory
agencies in developed and developing countries. Unfortu-
nately, in our experience very few procurement agencies
comply with the MQAS, while few purchasers have the
capacity to assess the compliance of their procurement
agents with the MQAS.
In order to ﬁll the current gap between what these new
initiatives can currently deliver and the immediate need to
support medical programmes with a broad range of drug
requirements, MSF developed a qualiﬁcation system in
2003 to ensure that the drugs purchased by its procurement
centres are in line with WHO standards. MSF’s qualiﬁca-
tion system draws on existing international procedures,
standards and speciﬁcations (WHO 1997, 1999d, 2004c,
2006f, 2007b, Maponga & Ondari 2003) to assess speciﬁc
product dossiers and manufacturing sites (Box 2). This
qualiﬁcation process is only undertaken for drugs not
already validated by stringent regulatory agencies or the
Box 2 Outline of MSF’s qualiﬁcation system
Manufacturing site assessment for GMP
compliance: Sites approved in the previous 2 years by
internationally recognized inspectors* are approved de
facto by MSF. Other sites of potential interest are
audited by a consultant GMP expert.
Product evaluation: Once WHO GMP compliance is
established, MSF pharmacists undertake product
evaluation using classic quality indicators organizing in
the following categories: country of origin⁄countries of
registration of the product; stability studies; ﬁnished
product speciﬁcations; active pharmaceutical
ingredients; packaging⁄labelling⁄patient information;
GMP status of the manufacturing site; and proof of
therapeutic equivalence when required.
Decision process: On the basis of this information
products are then approved or rejected for use in MSF
programmes. This decision is communicated to the
producer.
No quality source identiﬁed: There are sometimes cases
where the technical information provided by the
producers is not sufﬁcient to validate the product.
MSF’s primary mandate is to provide emergency
medical assistance and the drug quality assessment
cannot be detrimental to the ability to respond to
emergency needs. A balanced risk-beneﬁt assessment is
done by the Medical Directors and, if the product is to
be accepted, a temporary exceptional authorization to
supply is granted. The result of the evaluation is
available for the National Drug Regulatory Authorities
(if they exist).
*Member inspectorates of the Pharmaceutical Inspec-
tion Co-operation Scheme, the International Conference
on Harmonization or the WHO Pre-qualiﬁcation pro-
ject.
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pharmacists with the assistance of external experts for
particular areas that require specialized assistance such as
bioequivalence studies or GMP audits.
Discussion
Signiﬁcant resources have been devoted to tackle counter-
feit medicines, but very little speciﬁc attention has been
given to the far more serious and widespread problem of
substandard medicines. This is partly a consequence of the
poor differentiation made between these two distinct
problems. However, reducing the problem of substandard
medicines to a consequence of counterfeiting skews
resources towards legal action alone, complicating efforts
to deﬁne targeted strategies to speciﬁcally address the
problem of the substandard medicines. The focus of
attention should rather be on the detection and removal of
poor quality medicines, whether they are counterfeit or
not, while at the same time assisting legitimate manufac-
turers to improve the quality of their pharmaceutical
production.
The limited resources available for the development of
efﬁcient pharmacovigilance systems in developing coun-
tries compound the problem. Because the consequences of
substandard medicines, both on individuals and on public
health, often go unreported, there is no stimulus to
intervene.
The pre-qualiﬁcation programme has recently been
expanded but capacity remains limited, and the majority of
essential drugs remain outside of the scope of the
programme and are still purchased without a proper
evaluation. Other recent initiatives by WHO are important
but remain ﬁnancially fragile; moreover, these measures
will be only successful if other actors involved in drug
procurement assume their responsibilities.
Donors have an important role to play by strengthen-
ing quality clauses based on WHO standards in the
tender mechanisms they impose on non-governmental
organizations. Likewise, drug purchasers (NGOs, inter-
national organizations, charities, and national purchase
centres in resource-limited countries) should assume their
responsibility towards protecting patients’ health and
insist that producers and distributors supply drugs that
meet WHO standards. Quality assurance is a mandatory
preliminary to drug purchases in the West, and there is
no rationale for this procedure to be any different when
drugs are exported to poor populations. Governments
could act now to reduce this problem by granting export
authorization only to pharmaceutical products that
comply with the WHO standards for quality, efﬁcacy and
safety.
Developing country governments can make important
improvements with minor investments, particularly by
making more use of technical resources that are already
available from WHO and other organizations. This would
be further enhanced through regional collaboration.
The reality today is that health care providers in resource-
poor settings are ﬁnding it increasingly difﬁcult to ﬁnd
sustainableandaffordablesourcesofessentialqualitydrugs.
Confronted with situations where no quality assured prod-
uct is available, they must make the impossible calculation
of weighing the risk of not treating against that of using a
drug whose quality and safety is unknown. This unaccept-
able situation will continue and in all likelihood worsen
unless those responsible assume their responsibilities.
Acknowledging the problem would be a good place to start.
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